Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review-Reference-Cited by-同舟云学术

Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review

Published:2024-03-27 Issue:7 Volume:20 Page:735-743
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Abedalweli Rand¹,Nguyen Michelle²,Deodhar Atul³

Affiliation:

1. Department of Medicine, Oregon Health & Science University/Hillsboro Medical Center, Portland, OR, USA

2. Department of Medicine, Providence St. Vincent Hospital, Portland, OR, USA

3. Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2024.2327589

Reference27 articles.

1. The current standard of care and the unmet needs for axial spondyloarthritis

2. Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis

3. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

4. Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate

5. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies;Expert Review of Clinical Immunology;2024-07-29